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Abstract
The Foundation for the NIH (FNIH) Sarcopenia Project validated cutpoints for appendicular lean 
mass (ALM) to identify individuals with functional impairment. We hypothesized the prevalence 
of sarcopenia and sarcopenic obesity would be similar based on the different FNIH criteria, 
increase with age, and be associated with risk of impairment limitations. We identified 4,984 
subjects ≥60 years from the National Health and Nutrition Examination Surveys 1999–2004. 
Sarcopenia was defined using: ALM (males<19.75kg; females<15.02kg), and ALM adjusted for 
body mass index (BMI) (males<0.789; females<0.512). Sarcopenic obesity is defined as subjects 
fulfilling criteria for sarcopenia and obesity by body fat (men≥25%; females≥35%). Prevalence 
rates of both sarcopenia and sarcopenic obesity were evaluated with respect to sex, age category 
(60–69, 70–79, >80years) and race. We assessed the association of physical limitations, basic and 
instrumental activities of daily living (ADL) and sarcopenia status. The mean age was 70.5 years 
in males and 71.6 years in females. Half (50.8%, n=2,531) were female, and mean BMI was 
28kg/m2 in both sexes. ALM was higher in males than in females (24.1 vs. 16.3; p<0.001) but fat 
mass was lower (30.9 vs. 42.0;p<0.001). In males, sarcopenia prevalence was 16.0% and 27.8% 
using the ALM and ALM/BMI criteria. In females, prevalence was 40.5% and 19.3% using the 
ALM and ALM/BMI criteria. Sarcopenia was associated with a 1.10 [0.86,1.41] and 0.93 
[0.74,1.16], and 1.46 [1.10,1.94] and 2.13 [1.41,3.20], risk of physical limitations using the ALM 
and ALM/BMI definitions in males and females, respectively. Prevalence of sarcopenia and 
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sarcopenic obesity vary greatly, and a uniform definition is needed to identify and characterize 
these high risk populations.
Keywords
sarcopenia; obesity; body fat; epidemiology; function
1. INTRODUCTION
One of the unfortunate consequences of people living longer[1] is the greater incidence of 
functional impairment and disability[2]. Impaired function in older adults is associated with 
a higher risk of institutionalization, mortality, and a compromised quality of life[3–5]. 
Sarcopenia, defined as the loss of muscle mass and strength with aging, is a strong predictor 
of adverse outcomes[6]. This syndrome is commonly observed in geriatrics practices and is 
increasingly recognized as an entity, even in surgical subspecialties[7].
Identifying patients with sarcopenia is critically important in order to target interventions for 
older adults who are at greatest risk. The standardized definition of sarcopenia varies 
throughout the literature[8]. Variation occurs because multiple mathematical constructs of 
the condition have been developed using different age cutoffs or on lower quintiles of a 
cohort being examined. Racial and ethnic differences in study and referent populations may 
also contribute to the variation in the prevalence. This creates an inherent challenge in 
applying cutoffs to populations that may have different characteristics than the one being 
examined.
The Foundation for the National Institutes of Health (FNIH) in 2014 was developed on the 
premise that clinically relevant cutpoints are associated with longitudinal adverse 
outcomes[9]. Based on large cohort studies, this group recognized both muscle strength (as 
represented by grip strength) and muscle mass, as two important determinants of future 
function. The purpose of our study was to apply the definitions from the FNIH consortium 
on a representative cohort of older adults to ascertain the prevalence of sarcopenia and 
sarcopenic obesity. We hypothesized that the two FNIH definitions of sarcopenia based on 
muscle mass would provide similar prevalence estimates of sarcopenia and sarcopenic 
obesity, increase with age, and be associated with functional impairments.
2. METHODS AND MATERIALS
A secondary analysis was conducted using data obtained from the National Health and 
Nutrition Examination Surveys (NHANES). NHANES is a cross-sectional survey 
representative of non-institutionalized older adults. NHANES uses a multistage probability 
sampling design, and is complex, stratified and oversamples minorities and older adults. The 
results provide excellent external validity to the rest of the United States population. The 
survey has been conducted by the Centers for Disease Control and Prevention since 1971, 
and its contents and procedures are fully available online at http://www.cdc.gov/nchs/
nhanes.htm (accessed February 2015). For this analysis, we restricted our sample to 
participants from the 1999–2004 datasets. The study was funded by internal Dartmouth 
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institutional funds. The local Institutional Review Board exempted this study from review 
due to the de-identified nature of the data.
There were 38,077 subjects screened, of which 31,125 were interviewed and 29,402 were 
examined in a standardized mobile examination center. Body composition data was 
ascertained using dual-energy X-ray absorptiometry (DEXA). We limited our analytic cohort 
to subjects aged 60 years and older, as sarcopenia and sarcopenic obesity are less prevalent 
and impact functional status less so in younger populations[8]. There were 4,984 subjects of 
all races (non-Hispanic White, non-Hispanic Black, Hispanic and Other). Subjects were also 
classified by age group where applicable (60–69.9, 70–79.9, and ≥80years).
All baseline data, including demographics, socioeconomic factors, and co-morbidities were 
assessed using a self-report questionnaire. All measurements were performed on the right 
side of the body to the nearest tenth of a centimeter, except where amputations, casts, and 
other factors prevented such an assessment. Weight was measured using an electronic digital 
scale, calibrated in kilograms, and height was measured using a stadiometer after deep 
inhalation. Body mass index (BMI) was calculated as weight (kg) divided by height(m) 
squared[10]. Waist circumference was measured standing, at the iliac crest, crossing the 
mid-axillary line, with the measuring tape placed around the trunk.
Functional status was assessed using self-reported questionnaires. All subjects were asked 
on a scale of 1 to 4 the degree of difficulty in performing a given activity (none to unable to 
do). Physical limitation (PL) questions, assessing mobility performance, included: walking 
¼ mile; walking up 10 steps; stooping, crouching and kneeling; lifting/carrying 10 pounds; 
walking between rooms on the same floor; and standing up form an armless chair. Subjects 
were classified as having ‘any difficulty’ if they indicated a response other than ‘no 
difficulty’ on the questionnaire. Subjects responding with ‘do not do, refused or don’t know’ 
were classified as having a limitation, in line with our previous analysis[11–13]. Any PL was 
defined as any difficulty of the aforementioned questions. Basic ADLs included: difficulty 
getting in and out of bed; using a fork, knife, or drinking from a cup; standing for long 
periods of time; and dressing yourself. NHANES did not have information on bathing or 
toileting. Having difficulty with any of these activities indicated basic ADL impairment. 
Lastly, we were only able to report on three instrumental ADLs[14], including managing 
money, performing house chores, or preparing meals, as this was the information that 
NHANES contained, as opposed to the eight well accepted ones[14]. Any physical, basic or 
instrumental ADL is considered a functional limitation.
Body composition measures were assessed using dual energy x-ray absorptiometry (DEXA) 
QDR-4500 Hologic scanner (Bedford, MA), by trained technicians. Subjects taller than 
192.5cm or weighing greater than 136.4kg were excluded from this assessment. All metal 
objects were removed, except false dentition and hearing aids. Fat mass, lean muscle mass, 
appendicular skeletal muscle mass of all limbs, and bone mineral content were assessed. 
Total body fat percent and lean mass percent were determined. All NHANES cycles 
performed similar operation procedures. Sarcopenia was defined using the two FNIH 
proposed definitions: ALM and ALM divided by BMI[9]. For men, the cutoffs were 
<19.75kg and <0.789, and in women, the cutoffs were <15.02kg and <0.512. Obesity was 
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defined using percent body fat using thresholds of 25% for males, and 35% for females 
(values used in our previous studies)[11, 13, 15, 16]. Additionally, subjects were classified 
as having obesity using the standard BMI category (≥30kg/m2) with sarcopenia. A diagnosis 
of sarcopenic obesity was considered if subjects fulfilled criteria for both sarcopenia and 
obesity using these definitions.
2.1 Statistical Analyses
We followed the policies and procedures as outlined by NHANES and analyzed the data 
accordingly (http://www.cdc.gov/nchs/nhanes). We present the unweighted counts of each 
group in Table 1 by sex, age group, and race. All baseline variables are represented as mean 
(standard error) for continuous variables, and count (weighted percentage) for categorical 
values. We intentionally stratified our results by sex because of considerable differences in 
body composition and its outcomes[17]. A t-test of unequal variances compared means 
between continuous variables and sexes, and a chi-square or Fisher exact test compared 
respective categorical variables. We identified individuals with sarcopenia, physical, basic 
ADL, and instrumental ADL limitations based on the ALM and ALM/BMI definitions by 
age category (≥60years, 60–69.9, 70–79.9, 80+), and by race (non-hispanic white, non-
hispanic black, Hispanic, other). We compared prevalence rates within each race and age 
category using weighted estimates, and determined whether differences existed between 
definitions using chi-square or Fisher exact tests.
Our primary analysis identified the association between each definition of sarcopenia and 
physical limitations, basic ADLs and instrumental ADLs. To identify this relationship, we 
created multivariable logistic regression models using NHANES weighting and accounted 
for the stratified clustered sampling. Subjects were assigned a binary outcome (yes/no) for 
physical, basic ADL and instrumental ADL limitations. Our primary predictor was whether 
a person had sarcopenia (yes/no). We performed separate analyses for each sarcopenia 
definition. Four models were created: Model 1 adjusted for age; Model 2 adjusted for age, 
race, smoking status (current, former, never); Model 3 adjusted for diabetes and arthritis; and 
Model 4 additionally adjusted for coronary artery disease. Odds ratios (95% confidence 
intervals) are presented for each multivariable model.
An exploratory analysis determined the prevalence rate of those with sarcopenia and obesity. 
Counts and weighted prevalence rates were assessed. We determined the prevalence rates of 
physical limitations in those with sarcopenia and obesity, and assessed differences between 
sarcopenic obesity definitions and sex. Within sex prevalence rates and between sex rates 
were compared using either chi-square or Fisher exact tests between ALM/BMI and ALM 
definitions using percent body fat for obesity, and ALM with body fat and BMI definitions 
for obesity, as well. Lastly, we reproduced our above models for the association between 
physical, basic ADL, and instrumental ADL limitations and sarcopenic obesity. All analyses 
were performed using STATA v.13 (College Station, TX). A two sided p-value of 0.05 was 
considered statistically significant.
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Sample sizes are indicated in Appendix A and baseline characteristics of the cohort are 
shown in Table 1. Females had lower waist circumference, muscle mass and ALM mass than 
males, as well as lower rates of diabetes and coronary artery disease. BMI was similar 
between the two sexes. Table 2 outlines the overall prevalence of sarcopenia using the two 
FNIH definitions by age, age group, and race category. Th prevalence of sarcopenia differed 
by definition type and increased with age in all sexes and races. In both sexes, Hispanics had 
a higher prevalence of sarcopenia than other races. Individual and composite limitations are 
presented in Table 3. Significant differences were observed between definitions in physical, 
basic ADL, and instrumental ADL limitations in both sexes.
We present the prevalence of sarcopenic obesity in Table 4 using both FNIH definitions for 
sarcopenia and body composition-defined obesity. Prevalence of sarcopenic obesity was 
27.3% and 12.5% using the ALM and ALM/BMI definitions, and 19.1% and 33.5% in men 
and women, respectively. The prevalence of sarcopenic obesity increased with age based on 
both definitions, yet the prevalence rate differed by sarcopenia definition for both sexes. The 
prevalence of sarcopenic obesity using the ALM/BMI definition was lower in females than 
in males, but higher in females using the ALM definition. Prevalence of physical, basic and 
instrumental ADL limitations was significantly higher in females than in males. Using a 
BMI≥30kg/m2, as an obesity measure for sarcopenic obesity, prevalence was markedly low 
across all sexes. Lastly, we present the multivariable analysis in Figure 1 and Appendix B of 
the association of sarcopenia or sarcopenic obesity and risk of functional impairments. In 
males, there are strong associations with functional impairments using the ALM/BMI 
definition for sarcopenia. The association with sarcopenic obesity in males was also 
observed in its relation with physical limitations. In females, ALM/BMI was strongly 
associated with functional impairment with all three domains for both sarcopenia alone, and 
for sarcopenic obesity.
4. DISCUSSION
Our results highlight the substantial prevalence of sarcopenia and sarcopenic obesity in a 
representative cohort of non-institutionalized adults using newly defined criteria for 
sarcopenia. Our hypothesis that these estimates increase with age was confirmed. However, 
we rejected our a priori determination that the prevalence rates would not differ by 
definitions. This study also confirms our previous hypothesis and adds to the body of 
literature demonstrating the strong association of sarcopenia and sarcopenic obesity with 
impairment in function[11, 18–26].
As anticipated, the prevalence rates and multivariable modeling findings differed by sex. 
Most importantly we found differences in prevalence rates by sarcopenia definition. 
Prevalence rates by age and ethnicity also varied. One notable exception was observed in 
non-Hispanic blacks; however, we suspect the lack of statistical differences between such 
prevalence rates was due to low study power in this subgroup. Physical limitations in both 
sexes were high in those with both sarcopenia and sarcopenic obesity. Our findings parallel 
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those of others that have demonstrated relationships with these subtypes and impact on 
physical function.
Using the ALM definition alone, no associations with physical limitations were observed in 
either sex. In contrast, impairment in instrumental ADL was observed, particularly in males. 
A shift from using muscle mass to muscle function (or strength) has been advocated as the 
prime determinant of identifying and studying sarcopenia[9]. A direct and strong causal 
pathway from mass to strength to function cannot be assumed. Only a subset demonstrates 
significant weakness that is associated with low muscle mass[9]. We also acknowledge that 
of the 3 instrumental ADLs in NHANES, household chores and preparing meals may be 
more dependent on muscle than the other cognitive ADLs, suggesting that these odds ratios 
may be somewhat higher than would otherwise be expected. While speculative, our results 
may reflect the phenomenon that ALM may not ideally reflect the degree of impairment in 
function.
Unfortunately there are no standard definitions for defining obesity. Different approaches 
that have been used include measures using DEXA, bioelectrical impedance, CT or 
magnetic resonance imaging. We used well known cutoffs proposed by the World Health 
Organization using body fat[15] as opposed to using other anthropometric measures such as 
waist circumference. Previous studies have categorized subjects as having sarcopenic obesity 
based on BMI[27] and we believe this may lead to bias. Our results suggest that using BMI 
leads to a markedly lower prevalence rate across both sexes. BMI is not a measure of fat, and 
has been proven to have poor sensitivity, incorrectly assessing adiposity in >50% of subjects, 
particularly in older adults[28]. BMI also accounts for muscle mass but not muscle strength 
and those with an elevated BMI may not fulfill criteria for sarcopenia based on ALM 
criterion. The modeling used to derive the FNIH thresholds proposed that lean mass be 
adjusted for body mass, as lean mass leads to the least amount of heterogeneity of future 
associations with incident mobility limitations[29]. Adjusting for BMI was meant to account 
for the degree of obesity, particularly in males. The results between definitions for those 
with sarcopenic obesity differ, both in prevalence and strengths of association. Our study 
used DEXA to accurately measure body fat which is recommended for body composition 
analysis[6]. We also observed that rates of sarcopenic obesity paralleled those of sarcopenia 
in both sexes, suggesting that the majority of persons were classified as having obesity by 
DEXA. When attempting to identify those with sarcopenic obesity, if DEXA is available, 
ALM alone should be considered for ascertainment of this entity.
The FNIH consensus agreed to certain cutoffs for the identification of sarcopenia. 
Importantly, these thresholds are based on the referent populations which have specific 
baseline characteristics. Measures of ALM are continuous in nature and introducing or 
altering a specific cutpoint may dramatically alter prevalence[30]. By dichotomizing ALM, 
subjects just above or just below the threshold may have similar risks to their counterpart but 
are not identified to be at high long-term risk. Clinicians should be aware of the potential for 
both over- and underdiagnosis of this clinical condition.
The NHANES datasets have several important limitations. First, the data are cross-sectional 
and only support associations and not causality. Therefore, increased adiposity and 
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sarcopenia could lead to disability. Alternatively, physical disability could result in muscle 
loss. Second, the results are highly dependent on the sampling approach and the limited set 
of survey variables. Third, the survey assesses only non-institutionalized older adults, 
omitting persons that have higher degrees of sarcopenia, including nursing home residents or 
those with severe disabilities. The findings are likely an under-representation of the true 
prevalence of these subgroups. Each population differs, including those of other developed 
nations, making external validity difficult. Fourth, this data set does not account for weight 
cycling (alterations in a person’s body composition over the life cycle), deconditioning, and 
other causes of functional decline[31]. We recognize that self-reported data was used and 
future analyses would be improved by using standardized functional assessments and/or 
objective standard measures of physical performance to limit bias. The study relied on 
definitions used in our previous studies[11–13] and thus may introduce minimal bias in non-
response rates, all of which are accounted after using NHANES’ analytical methods. 
NHANES lacked a complete set of functional variables reducing the generalizability and 
interpretation of our findings.
An important consideration is that subjects with obesity tend to acquire muscle reserves 
during the lifespan that allows them to compensate for their body habitus[32]. Our results 
may not reflect these individuals since the loss in the absolute quantity of muscle mass may 
not cross the sarcopenia threshold. Furthermore, fat infiltration may occur[26], particularly 
in those with sarcopenic obesity, leading to an underestimation of rates. FNIH also 
suggested the use of grip strength as a measure of muscle strength, or gait speed as its 
surrogate to identify individuals at risk for clinical weakness. Unfortunately, NHANES 
1999–2004 does not have any strength or walking speed data and is a limitation of this 
current study. Future studies should consider using these joint measures of strength and 
muscle mass not only to define prevalence rates but also to observe concordance between 
such measures in the assessment of an individual.
Our findings have considerable relevance in light of the recently published FNIH guidelines 
for sarcopenia. This is a commonly found geriatric syndrome in both sexes with high 
prevalence, irrespective of the definition used. By identifying subjects with sarcopenia, 
clinicians and researchers will be able to develop interventions to target this condition, 
reduce the risk of frailty, and preventing its occurrence and consequences. Further 
refinement of the criteria, particularly in ascertaining those with sarcopenic obesity is 
warranted to improve clinical identification and target appropriate care to those at risk.
FNIH criteria of sarcopenia applied to a representative cohort suggest elevated, but varying 
prevalence rates in the US population. Sarcopenia is associated with functional limitations in 
both sexes, however, longitudinal studies are necessary to validate these definitions in US 
based-cohorts.
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Appendix A
Unweighted Sample Sizes for Adults Aged 18 Years and Older by Sex, Age, and Race: 
NHANES 1999–2004
Categories by Age All Non-Hispanic White Non-Hispanic Black All Hispanics Other
Males 7,564 3,630 1,537 2,117 280
  Age ≥60 years 2,453 1,427 386 579 61
  60–69 years 1,061 490 223 317 31
  70–79 years 857 513 123 201 20
  ≥80 years 535 424 40 61 10
Females 8,307 3,915 1,689 2,394 309
  Age ≥60 years 2,531 1,419 425 623 64
  60–69 years 1,115 497 223 317 31
  70–79 years 778 439 135 181 23
  ≥80 years 638 483 63 81 11
Values represent individual subjects
All Hispanics include Mexican Americans
Appendix B
Association of Physical Limitations, Basic and Instrumental Activities of Daily Living with 
Definition of Sarcopenia
SARCOPENIA ALONE SARCOPENIA WITH OBESITY (Body Fat)
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Multivariable logistic regression estimates are represented as Odds Ratios (95% Confidence Intervals). The primary 
predictor was sarcopenia (yes/no). Referent Category is ‘no sarcopenia’ based on Foundation for the National Institutes for 
Health definitions, Appendicular Lean Muscle (ALM) cutoffs of: <19.75kg in males and <15.02kg in females; ALM/BMI 
cutoffs of <0.789kg in men and <0.512 in females. Separate models were created for the primary outcomes of Physical 
Limitations, Basic ADLs, and Instrumental ADLs.
Model 1: Adjusted for age
Model 2: Adjusted for age (Model 1), race + smoking status (current, former, never)
Model 3: Adjusted for Model 2 co-variates, and diabetes and arthritis
Model 4: Adjusted for Model 3 co-variates and coronary artery disease.
Estimates in bold face are statistically significant
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Association of Physical Limitations, Basic and Instrumental Activities of Daily Living 
with Definition of Sarcopenia in Males. Multivariable logistic regression estimates are 
represented as Odds Ratios (95% Confidence Intervals). The primary predictor was 
sarcopenia (yes/no) and sarcopenic obesity (yes/no), respectfully. Referent Category is ‘no 
sarcopenia’ based on Foundation for the National Institutes for Health definitions, 
Appendicular Lean Muscle (ALM) cutoffs of: <19.75kg in males and <15.02kg in females; 
ALM/BMI cutoffs of <0.789kg in men and <0.512 in females. Separate models were created 
for the primary outcomes of Physical Limitations, Basic ADLs, and Instrumental ADLs. 
Model 3 is represented, adjusted age, race, smoking status (current, former, never), diabetes 
and arthritis. * - indicates statistical significance
b-legend:
Association of Physical Limitations, Basic and Instrumental Activities of Daily Living 
with Definition of Sarcopenia in Females. Multivariable logistic regression estimates are 
represented as Odds Ratios (95% Confidence Intervals). The primary predictor was 
sarcopenia (yes/no) and sarcopenic obesity (yes/no), respectfully. Referent Category is ‘no 
sarcopenia’ based on Foundation for the National Institutes for Health definitions, 
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Appendicular Lean Muscle (ALM) cutoffs of: <19.75kg in males and <15.02kg in females; 
ALM/BMI cutoffs of <0.789kg in men and <0.512 in females. Separate models were created 
for the primary outcomes of Physical Limitations, Basic ADLs, and Instrumental ADLs. 
Model 3 is represented, adjusted age, race, smoking status (current, former, never), diabetes 
and arthritis. * - indicates statistical significance
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Table 1





Age, years 70.5 (0.18) 71.6 (0.25) <0.01
Anthropometry
  Weight, kg 85.1 (0.43) 72.0 (0.35) <0.01
  Body Mass Index, kg/m2 28.2 (0.11) 28.3 (0.13) 0.50
  High Body Mass Index, % 629 (29.8) 837 (33.2) 0.02
  Waist Circumference, cm 104.4 (0.32) 96.7 (0.30) <0.01
  Fat Mass, kg 27.0 (0.21) 31.1 (0.22) <0.01
  Fat Mass, % 30.9 (0.12) 42.0 (0.13) <0.01
  Total Lean Mass, kg 56.1 (0.23) 39.5 (0.16) <0.01
  Total Lean Mass, % 66.5 (0.01) 55.8 (0.01) <0.01
  Appendicular Lean Mass, kg 24.1 (0.12) 16.3 (0.09) <0.01
  ALM/BMI 0.86 (0.01) 0.58 (0.01) <0.01
Co-Morbidities
  Diabetes 542 (19.8) 518 (17.2) 0.06
  Coronary Artery Disease 521 (23.0) 349 (14.7) <0.01
  Arthritis 965 (41.0) 1,414 (57.3) <0.01
  Smoking
    Never 784 (30.6) 1,543 (59.1)
    Current 374 (13.9) 237 (10.3) <0.01
    Former 1,289 (55.4) 746 (30.6)
All values are mean (standard error of mean) or count (%) for continuous variables and counts (weighted percentages) for categorical variables by 
sex.
Total lean mass includes the entire body skeletal mass excluding bone mineral content. Appendicular lean muscle mass is defined as the lean mass 
of the sum of all the limbs (arms and legs) excluding bone mineral content.
A p-value represents a t-test of unequal variance (continuous variables) or a chi-square/Fisher exact test (categorical variables) between males and 
females
High body mass index is defined as ≥30kg/m2
Abbreviations: ALM – Appendicular lean Mass; BMI – Body mass index
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Table 3
Prevalence of Limitations by Sex and Low Muscle Mass Definition – Males and Females
Males Females
Physical Limitations ALM/BMI ALM ALM/BMI ALM
Walking ¼ mile 189 (31.3) 110 (25.1)† 219 (48.2) 306 (31.5) †
Walking up 10 steps 139 (23.0) 88 (19.3) * 181 (43.1) 243 (27.7) †
Able to stoop, crouch, kneel 387 (54.4) 218 (46.4) † 376 (66.4) 557 (52.0) †
Lift/carry 10 pounds 160 (20.1) 128 (23.4) † 261 (44.7) 415 (38.9) †
Walking between rooms on same floor 84 (10.0) 74 (12.1) * 87 (14.3) 109 (8.4)
Standing up from armless chair 204 (27.1) 122 (21.6) † 211 (36.7) 281 (25.1) *
Any Physical Limitation 346 (56.3) 207 (52.3) † 351 (74.7) 562 (60.8) †
Basic ADL limitation ALM/BMI ALM ALM/BMI ALM
Getting in and out of bed difficulty 140 (19.1) 80 (15.7) * 136 (21.6) 190 (15.6) *
Using fork, knife, drinking from cup 52 (6.1) 38 (7.4) * 41 (6.9) 72 (6.6)
Standing for long periods difficulty 340 (47.0) 201 (39.8) † 312 (59.3) 492 (47.6) †
Dressing yourself difficulty 108 (15.0) 59 (11.8) 99 (15.9) 150 (12.1)
Any Basic ADL limitation 369 (50.3) 228 (44.7) † 336 (62.8) 534 (51.6) †
Instrumental ADLs ALM/BMI ALM ALM/BMI ALM
Managing money 99 (11.9) 87 (16.3) * 85 (13.3) 164 (13.1) †
House chore 205 (27.6) 150 (27.1) * 241 (43.5) 350 (33.2) †
Preparing meals 130 (16.1) 107 (18.5) † 93 (12.9) 149 (11.4)*
Any IADL Limitation 264 (33.5) 191 (34.4) † 267 (47.4) 409 (37.9) †
Any Functional Limitation 394 (62.3) 242 (59.1) † 366 (78.7) 617 (68.0) †
Abbreviations: ADL – Activity of Daily Living; BMI – body mass index; FNIH – Foundation for the National Institutes of Health; IADL – 
Instrumental ADL Values represented are counts (weighted prevalences)
p-values comparing the proportions between either definition
Appendicular Lean Muscle (ALM) cutoffs are: men <19.75kg; females <15.02kg
ALM/BMI cutoffs are <0.789kg in men and <0.512 in females
Any Physical Limitation represents self-reported difficulty performing any of the physical limitations listed above; Any Basic ADL limitations 
represents self-reported difficulty performing any of the basic ADLs listed above; Any Instrumental ADL limitation represents a self-reported 





p-value<0.05; representing the difference between ALM/BMI and ALM prevalence rates within each category using a chi-square/Fisher exact test. 
All other values are considered non-significant (p>0.05)
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